Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.69 (
APC
)
16,337
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The enzyme NAD(P)H:flavin oxidoreductase (flavin reductase) catalyzes the reduction of soluble flavins by reduced pyridine nucleotides. In Escherichia coli it is part of a multienzyme system that reduces the Fe(III) center of
ribonucleotide reductase
to Fe(II) and thereby sets the stage for the generation by dioxygen of a free tyrosyl radical required for enzyme activity. Similar enzymes are known in other organisms and may more generally be involved in iron metabolism. We have now isolated the gene for the E. coli flavin reductase from a lambda gt11 library. After DNA sequencing we found an open reading frame coding for a polypeptide of 233 amino acids, with a molecular weight of 26,212 and with an N-terminal segment identical to that determined by direct Edman degradation. The coding sequence is preceded by a weak ribosome binding site centered 8 nucleotides from the start codon and by a promoterlike sequence centered at a distance of 83 nucleotides. In a Kohara library the gene hybridized to position 3680 on the physical map of E. coli. A bacterial strain that overproduced the enzyme approximately 100-fold was constructed. The translated amino acid sequence contained a potential pyridine nucleotide-binding site and showed 25% identity with the C-terminal part of one subunit (
protein C
) of methane monooxygenase from methanotropic bacteria that reduces the iron center of a second subunit (protein A) of the oxygenase by pyridine nucleotides.
...
PMID:Characterization of the flavin reductase gene (fre) of Escherichia coli and construction of a plasmid for overproduction of the enzyme. 205 Jun 27
The relationship between the repair processes occuring at the G2 phase of the cell cycle and cytogenetic damage in ataxia telangiectasia (AT) cells was studied. Lymphoblastoid cells derived from normal, heterozygote AT (HzAT) and three AT patients were exposed to X-rays or fission neutrons and post-treated with inhibitors of DNA synthesis/repair, such as inhibitors of DNA polymerases alpha, delta and epsilon (cytosine arabinoside, ara-C; aphidicolin,
APC
; buthylphenylen-guanine, BuPdG) or
ribonucleotide reductase
(hydroxyurea, HU). A strong increase of radiation-induced chromosomal aberrations was observed in normal and HzAT cells post-treated with ara-C,
APC
and HU, but not in the presence of BuPdG. No enhancing effect was observed in cells derived from AT patients, except for HU post-irradiation treatment. These results suggest that the enzymes that can be inhibited by these agents are not directly involved in the repair of radiation damage induced in G2 cells from AT patients, indicating that probably the AT cells that we used lack the capability to transform the primary DNA lesions into reparable products, or that AT cells might contain a mutated form of DNA polymerase resistant to the inhibitors.
...
PMID:Lack of effect of inhibitors of DNA synthesis/repair on the ionizing radiation-induced chromosomal damage in G2 stage of ataxia telangiectasia cells. 793 Aug 33
Colorectal cancer (CRC) ranks as the third-leading cause of cancer-associated mortalities in Taiwan. The expression of
ribonucleotide reductase
M2 (
RRM2
) and
p53R2
is associated with tumoral malignancy and progression in several types of cancer. The aim of the present study was to determine the association of
p53R2/RRM2
with the upstream expression of microRNA (
miR)-211
and the association of expression levels of
p53,
APC
and
k-ras
with clinical outcomes in patients with CRC. The study consisted of 192 tumor tissue samples obtained from patients with CRC. Immunohistochemistry and direct sequencing of DNA were performed to analyze
p53R2/RRM2
protein expression and
p53
/
APC
/k-ras
gene mutations in these samples. The expression level of
miR-211
was detected by reverse transcription-quantitative polymerase chain reaction. The results showed that the expression of
p53R2
was lower and that of
RRM2
was higher in patients with lymph node metastasis, distant metastasis, and late-stage CRC compared with patients without lymph node metastasis, distant metastasis and early-stage CRC. A high expression of
RRM2
in patients had a negative effect on overall survival (OS) and disease-free survival (DFS) in CRC. Positive expression of
RRM2
was detected in tumor tissues, and expression associated with the presence of
k-ras
gene mutation. Furthermore, it was detected that the upstream
miR-211
expression was negatively associated with
RRM2
expression in tumor tissues of patients with CRC.
miR-211
expression was associated with survival and tumoral recurrence in patients with
k-ras
mutations. The present authors suggest that the downregulation of
miR-211
and overexpression of
RRM2
in tumor tissues of patients with CRC could be used to predict metastases and disease prognosis, particularly in patients with
k-ras
gene mutations.
...
PMID:miR-211 regulates the expression of
RRM2
in tumoral metastasis and recurrence in colorectal cancer patients with a
k-ras
gene mutation. 2973 18